South Africa Recombinant Protein Therapeutics Cdmo Market Size & Outlook
South Africa recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
South Africa recombinant protein therapeutics cdmo market highlights
- The South Africa recombinant protein therapeutics cdmo market generated a revenue of USD 158.9 million in 2023 and is expected to reach USD 363.7 million by 2030.
- The South Africa market is expected to grow at a CAGR of 12.6% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 158.9 million |
| Market revenue in 2030 | USD 363.7 million |
| Growth rate | 12.6% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.8% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 312.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.52% in 2023. Horizon Databook has segmented the South Africa recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The existing need for advanced therapeutics & their manufacturing is a major factor driving the demand for recombinant protein therapeutics services in South Africa. This shows the existing growth possibilities for clinical research in the country. In addition, the entry & focus of small-scale CDMOs in South Africa are unveiling the future possibilities for advanced therapeutics development and manufacturing in the country.
The growing R&D activities and well-established research activities, which comply with the ICH and FDA standards; a diverse population; and low cost of trials are some of the primary factors expected to drive the market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Africa recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
South Africa Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
